On November 13, 2026 RGL-208 Injection, a dual-target in vivo CAR-T candidate independently developed by Regenelead, reported it has received implied clinical trial approval from the NMPA. It is intended for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. RGL-208 marks China’s first mRNA in vivo CAR-T product to enter clinical development, as well as Regenelead’s first in vivo CAR-T candidate advancing into the clinic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a partner of Regenelead, Medicilon provided pharmacokinetic and safety assessment studies for RGL-208, satisfying regulatory requirements for the NMPA, FDA and OECD, and enabling the candidate’s smooth transition into clinical testing.
Unmet Clinical Needs: Limitations of Current CAR-T Therapies
Conventional CAR-T therapies involve complex manufacturing and lengthy lead times, creating major barriers to patient access.
Relapsed/refractory B-cell hematological malignancies are highly heterogeneous and prone to recurrence, with poor outcomes for patients after multiple lines of treatment, representing a substantial unmet medical need. While several approved CAR-T products have offered curative potential, these existing therapies rely on ex vivo personalized manufacturing. The cumbersome workflows, long production cycles and high costs, paired with relapse risks driven by antigen loss and CAR-T cell exhaustion in single-target designs, severely limit accessibility. Expanding access so that more patients can rapidly receive CAR-T treatment remains one of the core challenges in cell therapy.
Dual-Target, Off-the-Shelf In Vivo CAR-T
Generating In Vivo CAR-T cells to advance cell therapy toward off-the-shelf solutions
RGL-208 Injection is a dual-target in vivo CAR-T candidate discovered and developed by Regenelead. As China’s first mRNA in vivo CAR-T product cleared for clinical investigation, it opens a new route to address key pain points of traditional CAR-T therapies and improve access to cell therapy.
mRNA-LNP delivery platform: mRNA encoding the CAR construct is specifically delivered to patients’ T cells to generate functional in vivo CAR-T cells, which recognize and eliminate tumor cells.

Dual-target design to mitigate relapse: By targeting two antigens simultaneously, RGL-208 helps reduce tumor escape caused by the loss or downregulation of a single antigen..

Off-the-shelf format without individualized manufacturing: Patients can be treated by a single intravenous administration — no leukapheresis, no waiting for in vitro manufacturing, drastically cutting waiting time.

Lower barriers for manufacturing and access: The mRNA-LNP platform offers the potential for standardized, large-scale manufacturing, which could reduce production costs and extend cutting-edge cell therapy to a broader patient population.

The IND approval of RGL-208 represents a landmark breakthrough for Regenelead in in vivo CAR-T research, placing the company among China’s front-runners for clinical translation of in vivo CAR-T programs. It further demonstrates the innovative strength and translational capacity of Regenelead’s proprietary technology platforms.

Platform-Driven Preclinical Support

Medicilon’s CGT platform powers preclinical development for cell and gene therapies

During RGL-208’s preclinical development, Medicilon deployed a suite of analytical platforms including flow cytometry, ELISA, PCR and LC-MS/MS to conduct systematic in vivo efficacy and toxicity evaluations. For the cynomolgus monkey toxicology program tailored to RGL-208, our team established immune-related response monitoring and emergency-response plans tailored to the product’s characteristics. In pharmacology studies using humanized immunodeficient mouse models, Medicilon precisely constructed the animal models and carefully controlled for model-related background lesions during data interpretation, delivering a scientifically rigorous and complete assessment of RGL-208’s efficacy and safety.

(Press release, Shanghai Medicilon, NOV 13, 2026, View Source [SID1234674753])